Perrigo, Mylan deal

Generics maker Mylan proposed to acquire Perrigo for $205 per share, or $28.9 billion, in cash and stock. The price is a 24% premium to Perrigo’s close of $164.71 on April 7, the day before the proposal was announced. Perrigo markets OTC drugs and generic prescription products and receives royalties on multiple sclerosis drug Tysabri natalizumab from Biogen Inc. (NASDAQ:BIIB, Cambridge, Mass.). ...